Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Filgotinib Dose De-escalation in Ulcerative Colitis (CAPYBARA)
NCT05479058Phase 3Terminated
- Sponsor
- Galapagos NV
- Start
- Jul 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial of filgotinib in ulcerative colitis (UC) (2 arms), sponsored by Galapagos NV. Primary endpoint: Percentage of Participants in Corticosteroid-free Clinical Remission Based on Modified Mayo Clinical Score (mMCS) at 48 weeks. Started Jul 2022; status: terminated.
02
Drugs
filgotinib
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT05479058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05479058.